🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

Recruitingn/aAges 25 Years - 90 YearsAllDiakonhjemmet Hospital
NCT06395883 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * diagnosis of inflammatory rheumatic joint disease * indication of disease modifying treatment initiation with or without glucocorticoids OR * stable DMARD treatment with parenteral glucocorticoid injection Exclusion Criteria: * known osteoporosis or osteoporosis treatment * women during the transitory phase * oestrogen treatment * any fracture within the last year * chronic glucocorticoid treatment * glucocorticoid treatment within the last year prior to inclusion * active cancer * kidney failure
💊

What it tests

  • Glucocorticoid Effect
📍

Where

2 sites
Vestre Viken HF, Drammen
Drammen, Norway
Diakonhjemmet hospital
Oslo, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy